A Pt(IV)-conjugated brain penetrant macrocyclic peptide shows pre-clinical efficacy in glioblastoma is a research paper published in Journal of Controlled Release (2022). On theSindex it has a DataRank of 0. It has been cited 27 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: R01 CA080024
NCI NIH HHS
Grant: R01 CA237063
NCI NIH HHS
Grant: R50 CA243706
NIEHS NIH HHS
Grant: P42 ES027707
NIEHS NIH HHS
Grant: P30 ES002109
National Science Foundation
Grant: 1122374
Graduate Research Fellowship Program
National Institutes of Health
Grant: 5R01CA237063-06
Fluorinated macrocyclic peptides as BBB penetrating agent for improved GBM treatment
National Institutes of Health
Grant: 2P30ES002109-11
TOXICOLOGY CORE UNIT
National Institutes of Health
Grant: 5R01CA080024-04
CHROMOSOMAL PROBES FOR MUTAGENESIS BY CARCINOGENS
National Institutes of Health
Grant: 3P42ES027707-03S1
Science and Engineering for Sensors, Mechanisms, and Biomarkers of Exposures
National Institutes of Health
Grant: 5R50CA243706-04
Innovative approaches for the advancement of glioblastoma therapies
FWCI
1.89
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals